

CONTENTS

<i>Contributors</i>	ix
<i>Preface</i>	xi
1. High-Performance Affinity Chromatography: Applications in Drug-Protein Binding Studies and Personalized Medicine	1
Zhao Li, Sandya R. Beeram, Cong Bi, D. Suresh, Xiwei Zheng, and David S. Hage	
1. Introduction	2
2. Frontal Analysis Studies of Drug-Protein Interactions	10
3. Zonal Elution Studies of Drug-Protein Interactions	17
4. Other Methods for Examining Drug-Protein Interactions	22
5. Conclusion	30
Acknowledgments	31
References	31
2. Role of Proteomics in the Development of Personalized Medicine	41
Kewal K. Jain	
1. Introduction	42
2. Protein Biomarkers	43
3. Protein Biochips	45
4. Role of Proteomics-Based Molecular Diagnostics in Personalized Medicine	48
5. Pharmacoproteomics	49
6. Concluding Remarks About Application of Proteomics for Personalized Medicine	50
References	51
3. Metabolomics and Personalized Medicine	53
Nadia Koen, Ilse Du Preez, and Du Toit Loots	
1. Introduction	54
2. The Value of "Omics" Technologies in the Development of Personalized Medicine	55
3. What is Metabolomics?	57
4. The Application of Metabolomics Toward Personalized Medicine	61
5. Concluding Remarks	73
Acknowledgments	74
References	74

4. Clinical Perspectives on Targeting Therapies for Personalized Medicine 79

Donald R.J. Singer and Zoulikha M. Zaïr

1. Introduction	80
2. What Are Personalized Medicines?	81
3. Rare Diseases	81
4. Evidence for Precision Medicines from Real World Data	82
5. Using "Real World" Data	82
6. Ethical Concerns	83
7. Adaptive Trial Design	84
8. Companion Diagnostics	85
9. Biological Treatments	86
10. Case Studies: Targets for Precision Medicines and Companion Diagnostics	88
11. Network Pharmacology	101
12. Future Developments	103
Acknowledgments	104
References	104

5. Personalized Medicine in Respiratory Disease: Role of Proteomics 115

V.S. Priyadharshini and Luis M. Teran

1. Introduction	116
2. Personalized Medicine	117
3. Proteomics	118
4. Respiratory Proteomics	120
5. Asthma	121
6. Chronic Obstructive Pulmonary Disease	124
7. Idiopathic Pulmonary Fibrosis	126
8. Aspirin-Exacerbated Respiratory Disease	128
9. Cystic Fibrosis	129
10. Lung Cancer	134
11. Conclusions	138
Acknowledgments	138
References	138

6. Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop 147

Theodore Sakellaropoulos, Junguk Hur, Ioannis N. Melas, Ellen Y. Guo,
Leonidas Alexopoulos, Mohammad Bohlooly, and Jane P.F. Bai

1. Introduction	148
2. Currently Approved Products Targeting Protein Kinases in Oncology	150

3. Tumor Heterogeneity	154
4. Computational Methods for Identifying Driver Mutations	157
5. Literature Mining in Oncology Research	163
6. Precise Genome Editing	166
7. Conclusion	169
Supplementary Material	170
References	170
7. Molecular Dynamics: New Frontier in Personalized Medicine	181
P. Sneha and C. George Priya Doss	
1. Introduction	182
2. Single Nucleotide Polymorphisms in Drug Response	186
3. Drug Discovery	187
4. Advent of Personalized Medicine	188
5. Evolution of Molecular dynamics in the Field of Macromolecule and Binding Interaction Analysis	189
6. Molecular Dynamics—A Boon in Personalized Medicine	191
7. MD Trajectories Analysis	198
8. Application of MD in SNP Analysis Toward Drug Discovery	205
9. Plausible Ways to Overcome the Disadvantages of Molecular Dynamics	207
10. Conclusion	211
Acknowledgments	212
References	212
8. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment	225
S.A. Syed Haneef and C. George Priya Doss	
1. Introduction	226
2. LSDs Classification	228
3. Treatment of LSDs	242
4. Pharmacological Chaperones Versus Chemical Chaperones	250
5. Combination Therapy for LSDs	250
6. How Can PCT Personalized?	251
7. Computational Studies in PCT	253
8. Advantages and Disadvantages of Various Therapies in LSDs	254
9. Future of PCTs	255
10. Conclusion	256
Acknowledgments	256
References	256

9. Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach	267
D. Thirumal Kumar and C. George Priya Doss	
1. Introduction	268
2. Materials and Methods	271
3. Results	273
4. Discussion	282
5. Conclusion	291
Acknowledgments	291
References	291
10. Role of von Willebrand Factor—A1 Domain Variants P1266L, H1268D, C1272R, and C1272F in VWD: A Molecular Modeling and Simulation Analysis Approach	299
C. George Priya Doss and Shabana Kouser Ali	
1. Introduction	300
2. Material and Methods	305
3. Results	308
4. Discussion	322
5. Conclusion	324
Acknowledgment	325
References	325
Author Index	331
Subject Index	373